Search
Vismodegib
go.drugbank.com/drugs/DB08828ApprovedInvestigational[A258608,L45803] In January 2012, vismodegib was approved by the FDA for the treatment of adult basal cell carcinoma.
Cysteamine
go.drugbank.com/drugs/DB00847ApprovedInvestigational[L15611] On August 25th 2020, the first ophthalmic solution for cystinosis requiring only 4 daily treatments was granted FDA approval.
Rimegepant
go.drugbank.com/drugs/DB12457ApprovedInvestigational[L11028] It received FDA approval on February 27, 2020 for the acute treatment migraine headache,[L11974] and was subsequently approved by the European Commission in April 2022 for both the treatment and
Ritlecitinib
go.drugbank.com/drugs/DB14924ApprovedInvestigationalIn June 2023, it was approved by the FDA for the treatment of severe alopecia areata in adults and adolescents 12 years and older.[L47092,L47127] It was further approved by the EMA in September 2023.
Sufentanil
go.drugbank.com/drugs/DB00708ApprovedInvestigationalSufentanil is an opioid analgesic that is used as an adjunct in anesthesia, in balanced anesthesia, and as a primary anesthetic agent. It is administered by the intravenous, epidural and sublingual routes. Also known as Dsuvia, the subli...
SBT-100
go.drugbank.com/drugs/DB17215ExperimentalIt was granted orphan drug designation by the FDA for the treatment of pancreatic cancer and osteosarcoma.[L44131,L44136]
Coal tar
go.drugbank.com/drugs/DB11082ApprovedCoal tar is a brown or black liquid of extremely high viscosity. Coal tar is among the by-products when coal is carbonized to make coke or gasified to make coal gas. Coal tars are complex and variable mixtures of phenols, polycyclic arom...
Mixtures: PREPARED COAL TAR 5% ET SALICYLIC ACID 2% OINTMENTSodium oxybate
go.drugbank.com/drugs/DB09072ApprovedInvestigational[L30598] An extended-release oral suspension formulation of sodium oxybate for narcolepsy, marketed under the brand name LUMRYZ, gained tentative FDA approval in July 2022 [L42645] and was fully approved
Nogapendekin alfa
go.drugbank.com/drugs/DB18740ApprovedInvestigational[L50592] This combination product was approved by the FDA on April 22, 2024, for the treatment of BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without
Synonyms: Il-15n72d:il-15rec-su/fc soluble complex iAnacaulase
go.drugbank.com/drugs/DB17449ApprovedInvestigational[A256047,A256052,A256057] The EMA approved the use of anacaulase in 2013,[A256047,A256052] and in January 2023, anacaulase received FDA approval.[L44717]